Stock Track | Moderna Plummets 5.11% Intraday as Hantavirus Vaccine Hype Fades Amid Institutional Skepticism

Stock Track05-20 03:59

Moderna, Inc. (MRNA) saw its stock price plummet 5.11% during intraday trading on Tuesday, marking a significant pullback for the biotech company.

The decline reflects a continued cooling of speculative enthusiasm around Moderna's early-stage hantavirus vaccine programs. Investment bank Evercore ISI issued a research note questioning the commercial viability of such a vaccine, explicitly stating that hantavirus is a low-incidence disease with limited market potential. The firm emphasized that recent stock volatility has been sentiment-driven rather than reflective of fundamental business changes.

This intraday movement signals ongoing profit-taking from a recent sharp rally, which was initially fueled by optimism around the hantavirus vaccine concept. While Moderna has confirmed preclinical research collaborations on an mRNA-based hantavirus vaccine, these programs remain in early stages with no disclosed clinical timeline, leading investors to reassess the near-term revenue potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131939898?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 03:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131939898","market":"sg","top_or_hot":-1,"title":"Stock Track | Moderna Plummets 5.11% Intraday as Hantavirus Vaccine Hype Fades Amid Institutional Skepticism","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) saw its stock price plummet 5.11% during intraday trading on Tuesday, marking a significant pullback for the biotech company.</p><p>The decline reflects a continued cooling of speculative enthusiasm around Moderna's early-stage hantavirus vaccine programs. Investment bank Evercore ISI issued a research note questioning the commercial viability of such a vaccine, explicitly stating that hantavirus is a low-incidence disease with limited market potential. The firm emphasized that recent stock volatility has been sentiment-driven rather than reflective of fundamental business changes.</p><p>This intraday movement signals ongoing profit-taking from a recent sharp rally, which was initially fueled by optimism around the hantavirus vaccine concept. While Moderna has confirmed preclinical research collaborations on an mRNA-based hantavirus vaccine, these programs remain in early stages with no disclosed clinical timeline, leading investors to reassess the near-term revenue potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Plummets 5.11% Intraday as Hantavirus Vaccine Hype Fades Amid Institutional Skepticism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Plummets 5.11% Intraday as Hantavirus Vaccine Hype Fades Amid Institutional Skepticism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-20 03:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) saw its stock price plummet 5.11% during intraday trading on Tuesday, marking a significant pullback for the biotech company.</p><p>The decline reflects a continued cooling of speculative enthusiasm around Moderna's early-stage hantavirus vaccine programs. Investment bank Evercore ISI issued a research note questioning the commercial viability of such a vaccine, explicitly stating that hantavirus is a low-incidence disease with limited market potential. The firm emphasized that recent stock volatility has been sentiment-driven rather than reflective of fundamental business changes.</p><p>This intraday movement signals ongoing profit-taking from a recent sharp rally, which was initially fueled by optimism around the hantavirus vaccine concept. While Moderna has confirmed preclinical research collaborations on an mRNA-based hantavirus vaccine, these programs remain in early stages with no disclosed clinical timeline, leading investors to reassess the near-term revenue potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1131939898","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131939898","pubTimestamp":1779220781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) saw its stock price plummet 5.11% during intraday trading on Tuesday, marking a significant pullback for the biotech company.The decline reflects a continued cooling of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘中暴跌5.11%汉坦病毒疫苗炒作在机构质疑声中消退","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) saw its stock price plummet 5.11% during intraday trading on Tuesday, marking a significant pullback for the biotech company.The decline reflects a continued cooling of speculative enthusiasm around Moderna's early-stage hantavirus vaccine programs. Investment bank Evercore ISI issued a research note questioning the commercial viability of such a vaccine, explicitly stating that hantavirus is a low-incidence disease with limited market potential. The firm emphasized that recent stock volatility has been sentiment-driven rather than reflective of fundamental business changes.This intraday movement signals ongoing profit-taking from a recent sharp rally, which was initially fueled by optimism around the hantavirus vaccine concept. While Moderna has confirmed preclinical research collaborations on an mRNA-based hantavirus vaccine, these programs remain in early stages with no disclosed clinical timeline, leading investors to reassess the near-term revenue potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131939898","isCrawlerRequest":true}